The Digital Biomarkers Market in the United States is projected to grow significantly, reaching approximately $39.28 billion by 2033, driven largely by advancements in neurological disease monitoring and AI analytics.
The market, valued at $6.18 billion in 2025, is expected to expand at a compound annual growth rate (CAGR) of 22.7% between 2026 and 2033. This growth is fueled by the increasing adoption of digital biomarkers among healthcare providers, pharmaceutical companies, and research organizations. These entities are leveraging digital biomarkers for real-time patient monitoring, which is supported by the rise of wearable devices and mobile health applications.
Key industry developments highlight the integration of AI and digital health platforms. For instance, recent innovations include a urine-based autism screening test and an AI-powered digital pathology solution that enhances cancer diagnostics. These advancements represent a shift towards precision medicine, allowing for earlier clinical decision-making and improved patient outcomes.
As regulatory frameworks evolve, early adopters of digital biomarkers are positioned to benefit from new opportunities in remote monitoring and decentralized clinical trials. The collaboration between companies, such as Roche's acquisition of PathAI, underscores the strategic importance of integrating AI into biomarker discovery and diagnostics, paving the way for more effective healthcare solutions.